The published research literature has investigated: GHRH receptor activation in pituitary somatotroph cells Pulsatile release of endogenous growth hormone Subsequent IGF-1 elevation through downstream GH signaling Maintained natural feedback regulation through somatostatin and IGF-1 DPP-4-resistant pharmacokinetics from the trans-3-hexenoic acid modification The two compounds produce fundamentally different research effects: AOD-9604 produces lipolytic activity without affecting IGF-1 or broader GH-mediated signaling Tesamorelin produces full GH axis activation including IGF-1 elevation and broader GH-mediated effects Pharmacokinetic Comparison The compounds have different pharmacokinetic profiles: AOD-9604
Insufficient Water Volume 0.5mL added to a 5mg vial yields 10,000mcg/mL
Clinical Study 2
Your GP will manage your B12 treatment programme, which includes regular blood tests to monitor your levels and ensure the dosage and frequency of your injections are appropriate
Treatment duration and frequency should be determined by a veterinarian based on the animal's condition
Products offered by Purity Peptides are intended exclusively for laboratory research, analytical testing, and scientific investigation.These materials are not intended for human or veterinary use, consumption, administration, diagnosis, treatment, mitigation, cure, or prevention of any disease or medical condition.By purchasing from Purity Peptides, the purchaser acknowledges that all products are being acquired solely for lawful research purposes and will be handled in accordance with applicable regulations and accepted laboratory practices.The purchaser assumes responsibility for the proper handling, storage, and use of all materials